David Leslie Paterson, PhD, MBBS, reviews the Game Changer trial and evolving evidence showing that cefiderocol is a useful but pathogen-dependent option for gram-negative bloodstream infections—performing reasonably against Acinetobacter and Pseudomonas, but with clear limitations against NDM-producing metallo-β-lactamases—underscoring the growing role of rapid diagnostics, combination therapy, and agents such as aztreonam–avibactam in an increasingly complex resistance landscape.
This series explores the evolving landscape of skin and soft tissue infection management—highlighting frequent misdiagnosis, the limited role of new diagnostics, tailored empiric therapy, expanding use of long-acting and oral antibiotics, and the growing emphasis on streamlined care models and stewardship-driven treatment strategies.
An expert discusses how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, while declining vaccine uptake among younger populations threatens to leave vulnerable groups increasingly exposed to seasonal illness complications.
Pranita D. Tamma, MD, MHS, discusses the approach to the clinical care and management of patients with gram-negative resistant Pseudomonas aeruginosa infections and the latest data supporting these decisions.
George Sakoulas, MD, provides commentary on the treatment and management of challenging patients hospitalized for pneumonia with comorbidities, inclduing COPD, structural lung disease, asthma, and others.
Bruce Jones, PharmD, FIDSA, BCPS, provides insights on treating and managing patients who are hospitalized with staphylococcus aureus and who also have comorbidities, such as type 2 diabetes and higher BMI.
Bruce Jones, PharmD, FIDSA, BCPS, provides commentary on treating challenging patients with acute bacterial skin and skin structure infections with comorbidities, including type 2 diabetes, higher BMI, advanced age, and others.
Ann Falsey MD, and Edward Walsh MD, discuss the data and implications for the recent approval of the Moderna RSV vaccine, mRNA 1345 (mRESVIA).
Christian Sandrock, MD, MPH, FCCP, highlights key takeaways on approaching treatment of antimicrobial resistant gram-negative infections as presented in updated IDSA guidelines and ID week 2023.
George Sakoulas, MD, provides key insights on the management of soft tissue infections including the role of single-dose agents and treating patients in an outpatient setting.
An expert in infectious diseases shares treatment considerations and clinical strategies for the management of community acquired pneumonia (CAP).
An infectious disease clinical specialist provides insight on approaching treatment of complicated UTIs and shares the impact of the COVID-19 pandemic on treatment approach as well as the importance of antimicrobial stewardship.
A Discussion on Gram-Negative Pathogens and Managing Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Advances in Treating and Managing Skin and Soft Tissue Infections